InnSight Technology
InnSight Technology is a privately held medical device company developing the OcuCheck Biosensor, a point-of-care electrochemical platform that quantitatively measures tear fluid biomarkers to diagnose dry eye disease and screen for diabetes, targeting optometrists and eye care professionals.
- Company typePrivate
- Founded2014
- HeadquartersChampaign, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What InnSight Technology does
InnSight Technology (legal entity Innovations in Sight Technology, Inc.) is a privately held biotechnology and medical device company founded in 2014 and headquartered in Pittsburgh, Pennsylvania, with incorporation in Illinois. The company develops the OcuCheck Biosensor, a point-of-care diagnostic device that uses a specialized electrochemical biosensor with proprietary coatings to perform quantitative analysis of tear fluid biomarkers — most notably simultaneous measurement of MMP-9 and tear film osmolarity — delivering results within minutes in a lightweight, portable, durable form factor usable inside or outside a clinical setting.
The core technology is differentiated as a first-of-kind multiplex platform for tear fluid, reportedly validated across more than eight tear fluid proteins to enable diagnosis across conditions ranging from dry eye disease to diabetes. The proprietary sensor coatings and multiplex architecture form the basis of the company's competitive positioning, though no patents, trademarks, or regulatory clearances were disclosed in the source materials. Co-founders Dipanjan Pan (CTO) and Leanne Labriola (President) lead a small team organized across R&D, product development, clinical operations, and medical/strategic advisory functions, with clinical validation supported by University of Pittsburgh Medical Center affiliation.
The business model is sales-led hardware distribution to optometrists and eye care professionals for use in clinical and point-of-care settings, with value propositions anchored to dry eye disease under-diagnosis (patients reportedly seeing 2–3 doctors before correct diagnosis) and unmet needs in non-invasive diabetes screening and monitoring during optometry visits. Capital sources to date are modest — approximately $1.31M cumulative across NSF grants ($150K in 2015 and ~$1.06M in 2017), a $100K seed from AlphaLab Health and Innovation Works in 2022, and accelerator participation with SOSV HAX in 2025 — with the company actively seeking investors through a dedicated portal and having won the 2025 Eyecelerator Pitch Challenge.
InnSight Technology firmographics
Firmographics- Name
- InnSight Technology
- Legal name
- Innovations in Sight Technology, Inc.
- Website
- https://innsightech.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InnSight Technology is a privately held medical device company developing the OcuCheck Biosensor, a point-of-care electrochemical platform that quantitatively measures tear fluid biomarkers to diagnose dry eye disease and screen for diabetes, targeting optometrists and eye care professionals.
- Ownership category
- akta.pro rank
InnSight Technology industry classification
Industry- Product category
- Ophthalmic Diagnostic Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)
- akta.pro secondary industries
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)
Keywords
Where InnSight Technology is headquartered
LocationHeadquarters
- HQ city
- Champaign
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
InnSight Technology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- OcuCheck Biosensor Device Sales: Sale of point-of-care diagnostic devices for tear fluid analysis to healthcare providers including optometrists.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
InnSight Technology product offering
Product offeringCore offering
InnSight Technology develops and sells the OcuCheck Biosensor, a point-of-care diagnostic device that uses proprietary electrochemical sensor coatings to quantitatively measure tear fluid biomarkers, including MMP-9 and tear film osmolarity, in a single device. It is complemented by the company's Multi Platform Technology, the first multiplex platform for tear fluid analysis validated on more than eight tear fluid proteins, enabling non-invasive detection of dry eye disease and systemic conditions such as diabetes.
Product overview
InnSight Technology offers a unified product portfolio centered on the OcuCheck Biosensor, a point-of-care diagnostic device that leverages electrochemical sensor technology with proprietary coatings to perform quantitative tear fluid analysis. The core OcuCheck device is the only device that can simultaneously measure MMP-9 and tear film osmolarity in one device. This is complemented by the company's Multi Platform Technology, which represents the first multiplex platform for tear fluid analysis, enabling simultaneous testing of multiple tear fluid proteins. Together, these products enable non-invasive detection and diagnosis of eye conditions (such as dry eye) and systemic diseases (such as diabetes) through objective tear fluid biomarker measurements.
Differentiator
Problem solved
Functional benefit
Brands
- OcuCheck Biosensor: Revolutionary point of care device for tear fluid analysis providing quantitative measurement of tear fluid biomarkers including MMP-9 and tear film osmolarity
Companies that use InnSight Technology
Customer profileSegments3 records
Ideal customer profiles2 records
InnSight Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
InnSight Technology partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
InnSight Technology competitors and assessment
Company assessmentBroad incumbents
- Bausch + Lomb: Diversified eye-health company with a portfolio that includes dry-eye diagnostics and therapeutics. Comparable as a large incumbent selling into the same optometrist customer base as InnSight.
- Alcon: Global ophthalmic medical-device leader with surgical, vision-care, and dry-eye diagnostic offerings. Comparable as a broad incumbent in the optometry/ophthalmology channel where InnSight plans to commercialize OcuCheck.
- Dexcom: Market leader in continuous glucose monitoring. Comparable as the dominant non-invasive/multi-day diabetes monitoring incumbent that InnSight would face if it expands OcuCheck into diabetes management.
- Abbott Diabetes Care: Manufactures FreeStyle Libre continuous glucose monitors and other blood-glucose diagnostics. A major potential competitor if InnSight expands OcuCheck into non-invasive diabetes screening and monitoring.
- TearScience (Johnson & Johnson Vision): Acquired by Johnson & Johnson Vision, TearScience pioneered LipiFlow thermal pulsation and meibography for dry-eye diagnosis and treatment. Comparable as a dry-eye diagnostics franchise now backed by a global ophthalmic incumbent.
- QuidelOrtho: Large specialty diagnostics company with broad point-of-care and clinical-lab assay portfolios. Comparable as an established diagnostic-device incumbent with regulatory, manufacturing, and distribution scale InnSight lacks.
Emerging players
- NovaBay Pharmaceuticals: Small ophthalmic-focused company developing diagnostics and therapeutics for eye-care conditions, including dry eye. Comparable as a small, ophthalmic-focused peer working on novel eye-disease diagnostics and treatments.
- Rapid Pathogen Screening (RPS / now part of a larger diagnostics group): Develops point-of-care diagnostic tests for eye and other conditions using novel biosensor approaches. Comparable as a similarly sized specialty diagnostics developer with point-of-care ambitions in eye care.
Direct peers
- Trukera Medical (formerly TearLab): Maker of the TearLab Osmolarity System, the most widely deployed point-of-care tear osmolarity test in optometry. Trukera is the closest direct competitor to InnSight on tear-fluid-based dry-eye diagnostics and shares the same optometry channel.
- iCare (Icare Finland / Revenio Group): Maker of point-of-care ophthalmic diagnostic devices including tonometers and the iCare ILLOS tear-fern test for dry eye. Directly comparable as a small, specialized point-of-care ophthalmic diagnostics company selling to eye-care professionals.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
InnSight Technology social profiles
Digital presenceInnSight Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
InnSight Technology leadership team
Management profileNumber of profiles
Profiles2 records
InnSight Technology funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InnSight Technology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InnSight Technology
What does InnSight Technology do?
InnSight Technology develops and sells the OcuCheck Biosensor, a point-of-care diagnostic device that uses proprietary electrochemical sensor coatings to quantitatively measure tear fluid biomarkers, including MMP-9 and tear film osmolarity, in a single device. It is complemented by the company's Multi Platform Technology, the first multiplex platform for tear fluid analysis validated on more than eight tear fluid proteins, enabling non-invasive detection of dry eye disease and systemic conditions such as diabetes.
Is InnSight Technology a public or private company?
InnSight Technology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InnSight Technology founded?
InnSight Technology was founded in 2014. It employs 11 to 50 people.
Where is InnSight Technology based?
InnSight Technology is headquartered in Champaign, United States, in the North America region.
How does InnSight Technology make money?
One revenue line is on record: ocuCheck Biosensor Device Sales.
Who are InnSight Technology's main competitors?
Broad incumbents on record are Bausch + Lomb, Alcon, Dexcom, Abbott Diabetes Care, TearScience (Johnson & Johnson Vision) and QuidelOrtho. Emerging players are NovaBay Pharmaceuticals and Rapid Pathogen Screening (RPS / now part of a larger diagnostics group). Direct peers are Trukera Medical (formerly TearLab) and iCare (Icare Finland / Revenio Group).
Does InnSight Technology have an API?
No public API is recorded for InnSight Technology.
What industry is InnSight Technology in?
InnSight Technology's product category is Ophthalmic Diagnostic Medical Devices. Its primary akta.pro industry code is HLAHAJAF, Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation), with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 334510 and its SIC code is 3841.